EUCTR2014-001736-11-Outside-EU/EEAActive, not recruitingNot Applicable
Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly with Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico
Sanofi Pasteur SA0 sites732 target enrollmentStarted: May 26, 2014Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 732
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1) Aged 9 to 12 months on the day of inclusion.
- •2) Born at full term of pregnancy (= 37 weeks) and with a birth weight = 2.5 kg.
- •3) Subject in good health, based on medical history and physical examination.
- •4) Documentation of completion of the primary vaccination series with Pentaxim vaccine with 3 doses received between 2 and 8 months of age.
- •5) Informed consent form has been signed and dated by both parents or other legally acceptable representative (and by 2 mandatory witnesses as required by local regulations).
- •6) Subject and parent/guardian are able to attend all scheduled visits and to comply with all trial procedures.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 732
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1) Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination.
- •2) Planned participation in another clinical trial during the present trial period.
- •3) Planned receipt of any vaccine in the 4 weeks following any trial vaccination.
- •4) Previous vaccination against flavivirus diseases, measles, mumps, rubella, previous booster vaccination against pneumococcal diseases, diphtheria, tetanus, pertussis, Hib and/or polio.
- •5) Receipt of blood or blood-derived products in the past 3 months which might interfere with assessment of the immune response.
- •6) Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
- •7) Personal seropositivity for human immunodeficiency virus (HIV) or hepatitis C as reported by the parent(s)/legally acceptable representative.
- •8) History of pertussis and/or Hib infection as reported by the parent(s)/legally acceptable representative.
- •9) Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances.
- •10) History of contraindication to the receipt of vaccines containing components of Pentaxim vaccine (diphtheria toxoid, tetanus toxoid, PT, FHA, PRP and polio) or of MMR (measles, mumps and rubella) vaccine or of pneumococcal conjugate vaccine.
- •11) Thrombocytopenia, as reported by the parent(s)/legally acceptable
- •representative.
- •12) Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination.
- •13) History of central nervous system disorder or disease, including seizures.
- •14) Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.
- •15) Identified as a child (adopted or natural) of the Investigator or of site employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center.
- •Temporary Exclusion Criteria:
- •A prospective subject must not be included in the study until the following conditions and/or symptoms are resolved:
- •16) Febrile illness (temperature = 38.0°C) or moderate or severe acute
- •illness/infection (according to Investigator judgment) on the day of vaccination.
- •17) Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Study to Evaluate the Immune Response after a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly with a Licensed Meningococcal Serogroup B Vaccine,in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y and W)MedDRA version: 20.0Level: PTClassification code 10027274Term: Meningococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-004461-41-Outside-EU/EEASanofi Pasteur Inc570
Active, not recruiting
Not Applicable
Safety and Immunogenicity of Booster Vaccination with PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Booster Vaccination with Infanrix® hexa when Both Vaccines Are Co-Administered with Prevenar® to Toddlers 11-18 Months of AgePEDIACEL is a fully liquid combination vaccine indicated for infants and children for the prevention of five infectious diseases (diphtheria, tetanus, pertussis, poliomyelitis and infections caused by Haemophilus influenzae type b), as a booster dose administered to toddlers previously primed with three doses of a hexavalent vaccine.EUCTR2006-000898-30-DESanofi Pasteur Incorporated
Not yet recruiting
Not Applicable
Booster dose for Covid-19CTRI/2022/02/040563Asian Healthcare Foundation
Completed
Phase 4
Intradermal second booster COVID-19 vaccinatioThe second booster intradermal mRNA-based vaccine following the 2-dose primary series of ChAdOx1 (AstraZeneca) can provide a sufficient level of immunity against SAR-CoV-2.booster vaccine, SAR-CoV2, older adult, intradermal vaccination, elderly, ThailandTCTR20230411008Faculty of Medicine Siriraj hospital, Mahidol University107
Not yet recruiting
Phase 4
Safety and Immunogenicity of a booster dose of inactivated Vero-cell-derived Japanese Encephalitis vaccine (JEVAC) in children whom primed with live attenuated JE vaccine.Healthy childrenJapanese encephalitisJapanese encephalitis vaccineImmunogenicityBoosterInactivated JE vaccineTCTR20190507007iaoning Cheng Biotechnology, Shenyang150